1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Livtencity FDA Application Multi-Discipline Review, Nov 23, 2021. Retrieved Dec 6, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf
2. Mullard A. FDA approves decades-old maribavir for CMV infection. Nature Reviews Drug Discovery. 2021;21(1):9–9.
3. Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. Published online December 2, 2021:ciab988.
4. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–292.
5. Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19(4):215–229.